UNSPSC 51283904: Silvadene or silver sulfadiazine

This classification denotes a topical anti-infective agent and sulfonamide anti-infective agent with the molecular formula C10H9N4O2S.Ag, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W46JY43EJR, chemically known as sulfanilamide, n(sup 1)-2-pyrimidinyl-, monosilver(1+) salt but generally known as silver sulfadiazine, which bears US NIH Compound Identifier 31011. European Medicines Agency schedules Silver sulfadiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04622MIG.

World Health Organization schedules silver sulfadiazine in its Anatomical Therapeutic Chemical (ATC) Classification. Silvadene or silver sulfadiazine bears US NLM identifiers UMLS ID C0723179 and NCI Concept Code C66567. SMILES: C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+].

UNSPSC 51283904 Silvadene or silver sulfadiazine is a Commodity code that captures state and local procurement of pharmaceutical products and medical supplies, though the recent opportunities posted under this code show limited direct alignment with the nominal silvadene scope. The recent solicitations reveal that state and local governments are actually buying a much broader array of medical and pharmaceutical items — generic multi-source pharmaceuticals, over-the-counter products, naloxone, medical first aid supplies, and direct-to-manufacturer prescription fulfillment capabilities. Issuing bodies include state health and human services agencies (Texas HHS Commission, Minnesota Department of Administration), county health departments (Seminole County, Florida), city fire departments and purchasing offices (City of Tampa), and multistate cooperative purchasing alliances (MMCAP). Solicitations span RFPs for cooperative pharmaceutical contracting, RFIs for pharmacy benefit program design, ITBs for medical first aid supplies, and IFBs for naloxone and drug deactivation systems. The scope extends from consumable medical supplies to direct manufacturer relationships and value-based pharmacy contracting, indicating that the code is being used to capture pharmaceutical and medical supply procurement more broadly than silvadene alone.

Geographic activity centers on Minnesota (through MMCAP's multistate cooperative, which includes Oregon participants), Florida (Seminole County), and Texas (HHS Commission), with additional activity in Florida through the City of Tampa. Representative recent opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the City of Tampa's ITB 26-P-00145 for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000, with a designated small local business enterprise set-aside and a 5 percent bid discount, due March 13, 2026; the Minnesota MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; and the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities, posted April 3, 2026.